Nordicus Partners CORP 8-K filings

Nordicus Partners Corporation announced the immediate resignation of Andrew J. Ritter from its Board of Directors and its committees, effective July 7, 2026.

Nordicus Partners Corporation announced the establishment of its Audit, Compensation, and Nominating Committees, along with the adoption of their respective charters.

Nordicus Partners Corporation announced the completion of a private offering, issuing 131,000 restricted common shares to ten investors at $2.75 per share, raising $360,250.

Nordicus Partners Corporation completed a private offering, issuing 416,000 restricted common shares to eight investors at $2.75 per share, raising $1.14 million.

Nordicus Partners Corporation completed a private offering, issuing 1,057,500 restricted common shares to 54 investors at $1.90 per share, raising approximately $2 million.

Nordicus Partners Corporation has furnished independent valuation reports for its wholly-owned subsidiaries, Orocidin A/S and Bio-Convert A/S, to analysts and investors.

Nordicus Partners Corporation announced the expansion of its Board of Directors from three to five members, appointing three new directors with extensive experience in finance, corporate governance, and life sciences.

Nordicus Partners Corporation announced the completion of a private placement, issuing 35,000 restricted common shares at $4.00 per share to a private investor, raising $140,000.

Nordicus Partners Corporation announced the approval of new employment and consulting agreements for its CEO, Henrik Rouf, and CFO, Bennett J. Yankowitz, effective July 1, 2025, detailing their updated compensation and terms.

Nordicus Partners Corporation announced the completion of a private offering, issuing 54,000 restricted common shares to two private investors at $5.00 per share, raising $270,000.

Nordicus Partners Corporation will present to analysts and investors regarding its Bio-Convert A/S subsidiary, with the presentation available on the company's website.

Nordicus Partners Corporation will present an update on its wholly-owned subsidiary, Orocidin A/S, to analysts and investors starting March 6, 2025.

Nordicus Partners Corporation has released a presentation for analysts and investors, providing a summary of information previously disclosed in SEC filings.

Nordicus Partners Corporation has issued a warrant to GK Partners ApS for the purchase of 1,000,000 shares of its common stock, exercisable until December 31, 2025.

Nordicus Partners Corporation has entered into agreements with Harbor Access LLC and ESG Advisor Group, L.L.C. for investor relations and consulting services.

Nordicus Partners Corporation has acquired the remaining 5.34% of Orocidin A/S, making it a wholly-owned subsidiary through a stock-based transaction.

Nordicus Partners Corporation has acquired Bio-Convert ApS, a clinical-stage biopharmaceutical company, in an all-stock transaction, issuing 12 million restricted shares of its common stock.

Nordicus Partners Corporation has appointed Peter Severin as Chairman of the Board, replacing Christian Hill-Madsen who resigned to focus on Orocidin A/S.

Nordicus Partners Corporation has acquired a 95% stake in Orocidin A/S by issuing 38 million restricted common shares to the selling shareholders.